COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Bridging Trial to Compare the PK Profile When Glepaglutide is Administered Via Vial/Syringe Versus Autoinjector.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04318743
Recruitment Status : Recruiting
First Posted : March 24, 2020
Last Update Posted : March 24, 2020
Information provided by (Responsible Party):
Zealand Pharma

Brief Summary:
This is an open-label, randomized, single center, 2-treatment, 3-period, 3-sequence reference-replicated, crossover trial in healthy subjects to compare the PK of glepaglutide (ZP1848) after a single SC administration by vial/syringe and by autoinjector.

Condition or disease Intervention/treatment Phase
Healthy Drug: Glepaglutide Phase 1

Detailed Description:
A total of 72 subjects will be randomized in a 1:1:1 ratio to receive 10 mg glepaglutide SC via vial/syringe (Reference) twice or autoinjector (Test) in one of the 3 treatment sequences.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 72 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Bridging Trial to Compare the Pharmacokinetics of Glepaglutide (ZP1848) After Single Subcutaneous Adminstration by Vial/Syringe and by Autoinjector in Healthy Subjects: a Phase 1, Randomized, Open-label, Three-way, Reference-replicated Crossover Trial.
Actual Study Start Date : March 4, 2020
Estimated Primary Completion Date : September 21, 2020
Estimated Study Completion Date : September 21, 2020

Arm Intervention/treatment
Experimental: autoinjector - vial/syringe - vial/syringe
Single dose of Glepaglutide 10 mg for each treatment sequence
Drug: Glepaglutide
Other Name: ZP1848

Experimental: vial/syringe - autoinjector - vial/syringe
Single dose of Glepaglutide 10 mg for each treatment sequence
Drug: Glepaglutide
Other Name: ZP1848

Experimental: vial/syringe - vial/syringe - autoinjector
Single dose of Glepaglutide 10 mg for each treatment sequence
Drug: Glepaglutide
Other Name: ZP1848

Primary Outcome Measures :
  1. Cmax = maximum concentration of ZP1848total in plasma [ Time Frame: 16 weeks ]
  2. AUC0-t = area under the plasma ZP1848total concentration-time curve (AUC) from time zero to the last time point with a measurable concentration [ Time Frame: 16 weeks ]

Secondary Outcome Measures :
  1. Number of subject with AE/SAE as a measure of safety and tolerability [ Time Frame: 16 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Informed consent obtained before any trial-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject).
  2. Healthy male or female subject aged between 18 years and 65 years, both inclusive, at screening.
  3. Body mass index (BMI) >20.0 kg/m2 and <29.9 kg/m2, both inclusive, at screening.
  4. Willing to maintain a stable weight for the duration of the trial.
  5. In overall good health according to age (medical history, physical examination, vital signs, and laboratory assessments), as judged by the Investigator at screening.
  6. Able to comply with all trial procedures.

Exclusion Criteria:

  1. Significant medical history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder, as determined by the Investigator.
  2. Subject with a history of colon cancer or a history of other cancers within the last 5 years.
  3. Clinically significant abnormality from physical examination, standard 12-lead ECG, or vital signs measurements as determined by the Investigator.
  4. Clinically significant abnormality in hematology, clinical chemistry, or urinalysis as determined by the Investigator (congenital nonhemolytic hyperbilirubinemia [eg, Gilbert's syndrome] is acceptable).
  5. History of significant hypersensitivity, intolerance, suspected hypersensitivity to glepaglutide or related products, or allergy to any drug compound, food, or other substance, unless approved by the Investigator.
  6. Positive results for hepatitis B surface antigens (HbsAg), hepatitis C virus (HCV) antibodies and/or human immunodeficiency virus (HIV) 1 antigen or HIV 1/2 antibodies, at screening.
  7. Receipt of blood products within 2 months prior to screening.
  8. Donation of blood or significant blood loss from 8 weeks prior to screening, plasma from 2 weeks prior to screening, or platelets from 6 weeks prior to screening.
  9. Use of any prescription medications/products (other than oral, implantable, transdermal, injectable, or intrauterine hormonal contraceptives) within 14 days prior to Day -1, unless deemed acceptable by the Investigator.
  10. Use of any nonprescription, over-the-counter medication/products, including vitamins, minerals, and phytotherapeutic/herbal/plant-derived preparations, within 7 days prior to Day -1 unless deemed acceptable by the Investigator. Up to 2 grams per day of acetaminophen is allowed at the discretion of the Investigator.
  11. Use of any medications/products known to be strong inhibitors or strong inducers of cytochrome P450 3A enzyme, including St. John's wort, within 30 days prior to Day -1, unless deemed acceptable by the Investigator.
  12. Have previously received the investigational product.
  13. Receipt of any investigational product within 60 days prior to Day -1. Participation in more than 3 other drug studies in the 10 months prior to Day -1 in the current trial.
  14. Previous exposure to glucagon-like peptide-1 (GLP-1), GLP-2, or analogs thereof. Previous exposure to human growth hormone, somatostatin, dipeptidyl peptidase-4 inhibitors, or analogs thereof within 6 months prior to screening.
  15. Have previously completed or withdrawn from this trial or any other trial investigating glepaglutide.
  16. History of alcoholism or drug/chemical abuse within 2 years prior to screening.
  17. Current alcohol consumption of >21 units per week for males and >14 units for females. One unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL wine).
  18. Positive urine drug screen (confirmed by repeat).
  19. Use of tobacco, smoking cessation products, or products containing nicotine (including but not limited to cigarettes, e-cigarettes, pipes, cigars, chewing tobacco, nicotine lozenges, or nicotine gum ) within 3 months prior to screening.
  20. Poor peripheral venous access.
  21. Positive qualitative serum pregnancy test (serum human chorionic gonadotropin) (female subjects only).
  22. Female who is pregnant, breastfeeding, intends to become pregnant in the immediate future.
  23. Female subject of childbearing potential who is sexually active without using adequate contraceptive methods (see Section 3.4.8) from 4 weeks prior to first admission to the clinical research center until 3 months after the last dose of trial product.*
  24. Male subject, who is not surgically sterilized and sexually active with a female partner of childbearing potential, and who is not willing to use adequate contraceptive methods (see Section 3.4.8), from the first dosing until 3 months after the last dose of trial product.
  25. Subjects whom, in the opinion of the Investigator, should not participate in this trial.
  26. Employee of PRA or the Sponsor or otherwise dependent. * Participant is of nonchildbearing potential, if she is either surgically sterilized (ie, by tubal ligation or removal of ovaries), has undergone complete hysterectomy, or is in a menopausal state (ie, at least one year without menses and a serum follicle-stimulating hormone [FSH] >40 IU/L at screening).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04318743

Layout table for location contacts
Contact: Ebru Ucar, MSc +45 5060 3835

Layout table for location information
PRA Health Sciences- Location Martini Recruiting
Groningen, NZ, Netherlands, 9728
Sponsors and Collaborators
Zealand Pharma
Layout table for additonal information
Responsible Party: Zealand Pharma Identifier: NCT04318743    
Other Study ID Numbers: ZP1848-19045
First Posted: March 24, 2020    Key Record Dates
Last Update Posted: March 24, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No